News
The cost of high-end, breakthrough medications traumatizes patients and their families. According to USAfacts, “national ...
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
Swedish biotech Hansa Biopharma on Friday released encouraging top-line results from three patients with Duchenne muscular ...
Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...
Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their ...
I understand the heartbreak of watching someone you love spiral. But compassion cannot mean locking people up,” writes a STAT ...
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...
4d
Amazon S3 on MSNThe story of Sarepta's Duchenne gene therapyThe last couple of weeks has been particularly distressing for Duchenne muscular dystrophy patients and their families. The ...
Susan Monarez, Ph.D., was confirmed by the Senate Tuesday as director of the Centers for Disease Control and Prevention (CDC) ...
A controversial hematologist-oncologist who joined FDA this spring and quickly became its top regulator has left the ...
In a 51–47 vote along party lines, the Senate confirmed Monarez as the director of the Centers for Disease Control and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results